RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE

Abdelmalek, Dina Adel; Abd-Elhamid, Basma Nagy; Abd Ellah, Noura Hassan; Ismail, Sayed

doi:10.21608/bfsa.2023.327652

RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE

Document Type : Original Article

Authors

¹ Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt

² Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt Department of Pharmaceutics, Faculty of Pharmacy, Badr University in Assiut, Naser city, Assiut, Egypt

10.21608/bfsa.2023.327652

Abstract

Prevalence of nonalcoholic fatty liver disease (NAFLD) affects more than 25% of the populations worldwide. In this study, resveratrol loaded solid lipid nanoparticles (Res-SLNs) were prepared by emulsification and were in vitro evaluated. Res-SLN 1 containing gelucire and tween 80 was selected for further in vitro and in vivo studies. In vivo studies were done via induction of NAFLD in rats with a high fat (HF) diet for 12-weeks followed by a 6-week period of treatment with Res-SLN1. Blood samples and liver sections were taken from rats for biochemical and histological evaluations. Res-SLN1 exhibited high entrapment efficiency (75±22%), small particle size (208±48 nm) and an acceptable release rate. In vivo studies demonstrated a remarkable improvement in lipid profile and liver enzyme with Res-SLN1. The histological features were significantly improved with Res-SLN1. Res-SLNs represent a promising therapeutic approach for NAFLD via prolonging Res release and ameliorating lipid profile and liver enzymes.

Keywords